Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte To Present Late-Breaking Phase 3 Results For Retifanlimab And Initial Data From Phase 1 CDK2 Inhibitor Program At The ESMO Congress 2024
Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year end 2024
- 總統論壇將在2024年年底之前計劃提交包括Phase 3 retifanlimab (Zynyz)在鱗狀細胞直腸肛門癌（SCAC）中的結果的補充生物製品許可申請（sBLA）
- Mini oral presentation to highlight initial Phase 1 data from potential first-in-class CDK2 inhibitor program in patients with CCNE1 ovarian and other advanced cancers
- 迷你口頭報告將突出展示在CCNE1卵巢癌和其他晚期癌症患者中可能是首例CDK2抑制劑計劃的初期Phase 1數據
- Incyte to host an in-person analyst and investor event to review key data at ESMO, including new results from a later CDK2 data cut-off, on Saturday, September 14, 2024, from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST)
- 因塞特將舉辦面對面的分析師和投資者活動，審查ESMO的關鍵數據，包括從較晚CDK2數據截止時點的新結果，時間爲2024年9月14日週六，下午1:00-2:30（歐洲中央夏令時晚上7:00-8:30）
Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2024, to be held September 13-17 in Barcelona and virtually.
因塞特（納斯達克：納斯達克）今天宣佈，公司將在即將舉行的2024年歐洲醫學腫瘤學會（ESMO）大會上展示其腫瘤學組合中的關鍵數據，該會議將於9月13日至17日在巴塞羅那和虛擬舉行。
譯文內容由第三人軟體翻譯。
